Edition:
United Kingdom

Poxel SA (POXEL.PA)

POXEL.PA on Paris Stock Exchange

7.32EUR
17 May 2019
Change (% chg)

€-0.14 (-1.88%)
Prev Close
€7.46
Open
€7.50
Day's High
€7.59
Day's Low
€7.22
Volume
116,172
Avg. Vol
135,476
52-wk High
€9.18
52-wk Low
€4.92

About

Poxel SAS is a France-based company principally engaged in the biopharmaceutical sector. The Company develops drugs with a focus on Type 2 diabetes. The Company aims at developing drugs from preclinical to phase 2 clinical proof of concept. Its lead product, Imeglimin, is in clinical phase 2 study for Type 2 diabetes indication.... (more)

Overall

Beta: --
Market Cap(Mil.): €144.47
Shares Outstanding(Mil.): 22.93
Dividend: --
Yield (%): --

Financials

  POXEL.PA Industry Sector
P/E (TTM): -- 69.30 32.55
EPS (TTM): -0.96 -- --
ROI: -74.43 8.91 13.82
ROE: -76.50 10.05 15.24

Earnings vs. Estimates